-
AcelRX Shares Should More Than Double On Painkiller Assets, Landenburg Says In Bullish Initiation
Thursday, August 16, 2018 - 11:19am | 436Read More...AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), with two product candidates in its pipeline, is a specialty pharma company focusing on pain management therapies. The Analyst Landenburg Thalmann analyst Michael Higgins initiated coverage of AcelRx with a Buy rating and $7 price target. The...
-
Ladenburg Thalmann Initiates Triplepoint Venture With Buy, $13.25 Price Target
Monday, May 2, 2016 - 10:01am | 469Read More...Ladenburg Thalmann has started TriplePoint Venture Growth BDC Corp(NYSE: TPVG) with a Buy rating and $13.25 price target, saying the firm's target markets are "growing to meet greater demand for new technologies and services," thereby providing significant opportunities for experienced venture...
-
The Opko Health Battle: High Short Interest with Heavy Insider Buying
Friday, June 15, 2012 - 7:49pm | 2343Read More...In the hyper-competitive biotech space, mid-cap name Opko Health (NYSE: OPK) is a classic battleground stock. The company's unorthodox structure, which houses a myriad of diverse, speculative, and complicated business lines, has led to wildly varying estimates of the stock's proper value. As a...
